Company intelligence / Profile preview

Vycellix

Tampa, Florida, United Statesvycellix.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Vycellix is advancing a suite of proprietary allogeneic and off-the-shelf NK and T-cell immunotherapies. Its lead program, VY‑UC-NK, is an off-the-shelf NK cell product candidate targeting hematological malignancies and is preparing to enter human clinical evaluation. The company’s platforms aim to overcome immune rejection and improve the efficacy, speed, and cost-effectiveness of next-generation cellular immunotherapies. Most programs are in preclinical or early development stages.[1][5][7]

Therapeutic areas
Oncology
Modalities
Allogeneic cell therapiesNatural Killer (NK) cellsT cell therapiesSmall molecules & RNA modulators[4][5]
Industry
Biotech
02

Drug pipeline

6 assets

VY-OZ

Preclinical

5 more assets in the full pipeline.

Request access →
03

Partnerships

Avectas (for nonviral gene delivery/cell manufacturing)[5]NextGenNK at Karolinska Institutet (collaborative partner)[1][5]

Beyond the preview

Go deeper on Vycellix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vycellix.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call